New Stock News | Maiketian (02041) starts its public offering today, with a compound annual growth rate of 38.9% from 2023 to 2025.

On August 28, Micotian (02041) announced that the company plans to globally offer 38.9106 million shares, including 3.8911 million shares for the Hong Kong offering and 35.0195 million shares for the international offering. The offering period runs from August 28 to September 2, with an offering price of HKD 15.42 per share, and a lot size of 100 shares, resulting in an entry fee of approximately HKD 1557.55. The total fundraising amount is expected to reach HKD 600 million, with a net fundraising amount of HKD 496 million. Micotian is expected to be listed on the main board on September 7, 2026, with Morgan Stanley Asia Limited and Huatai Financial Holdings (Hong Kong) Limited as joint sponsors. Regarding the use of proceeds, approximately 35% will be allocated for research and development to enrich the product line; about 20% will be used to develop manufacturing centers and expand production capacity; around 20% will be aimed at enhancing sales and marketing capabilities; about 10% will be used for global strategic investments and acquisitions; approximately 5% will be allocated for upgrading IT infrastructure; and around 10% will be used for working capital. Micotian is a global provider of medical devices capable of meeting the clinical needs of various departments, wards, and clinics within medical institutions, as well as community health centers, testing institutions, and home care settings. As of March 31, 2026, the company's product portfolio includes over 60 types of life-support products, 110 minimally invasive interventional products, and 150 in vitro diagnostic products, available in various models to meet diverse application requirements. The company's products have reached over 140 countries and regions worldwide. In China, its products have been supplied to over 6,000 hospitals, including about 90% of Grade A tertiary hospitals, covering 31 provinces, municipalities, and autonomous regions. It is understood that from 2023 to 2025, the companys revenue is projected to increase from RMB 1.313 billion to RMB 1.399 billion, and further to RMB 1.619 billion, with a compound annual growth rate (CAGR) of approximately 11%, and a year-on-year growth of 15.7% in 2025. During the same period, the company's gross profit is expected to rise from RMB 651 million to RMB 870 million, with the gross profit margin increasing from 49.6% to 53.7%, showing significant effects of scale and optimization of the product structure. Additionally, the adjusted net profit for 2025 is expected to reach RMB 129 million, with an adjusted profit of RMB 35 million in the first three months of 2026, far exceeding last years figure of RMB 15.1 million, reflecting a profit growth of over 130% during the adjusted period; the adjusted EBITDA is also expected to grow to RMB 290 million, with a CAGR of 38.9% from 2023 to 2025.